Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Forman

Showing results (991-1000 of 1,052) with videos related to

Pageof 106
Sort By:
Blood Advances|October 8, 2025
Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetrationLei Gao, Avyakta Kallam, Geoffrey Shouse, et al.
Transplantation and Cellular Therapy|August 9, 2024
Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell TransplantationShukaib Arslan, Amrita Desai, Dongyun Yang, et al.
Bone Marrow Transplantation|December 18, 2024
Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual diseaseAmanda Blackmon, Michelle Afkhami, Dongyun Yang, et al.
The Lancet. Haematology|May 18, 2026
Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trialAnthony Stein, Yan Wang, Monzr M Al Malki, et al.
Blood|March 22, 2022
Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICEMatthew G Mei, Hun Ju Lee, Joycelynne M Palmer, et al.
Neuro-Oncology|January 31, 2022
Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastomaChristine E Brown, Analiz Rodriguez, Joycelynne Palmer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 17, 2003
A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcomeH C Fung, A Stein, M l Slovak, et al.
The Lancet. Oncology|December 20, 2014
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyMax S Topp, Nicola Gökbuget, Anthony S Stein, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 4, 2019
Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase MutationsAmandeep Salhotra, Michelle Afkhami, Dongyun Yang, et al.
British Journal of Haematology|December 20, 2016
RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106Robert W Chen, Hongli Li, Steven H Bernstein, et al.
Pageof 106

Showing results (991-1000 of 1,052) with videos related to

Sort By:
Pageof 106
Blood Advances|October 8, 2025
Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetrationLei Gao, Avyakta Kallam, Geoffrey Shouse, et al.
Transplantation and Cellular Therapy|August 9, 2024
Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell TransplantationShukaib Arslan, Amrita Desai, Dongyun Yang, et al.
Bone Marrow Transplantation|December 18, 2024
Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual diseaseAmanda Blackmon, Michelle Afkhami, Dongyun Yang, et al.
The Lancet. Haematology|May 18, 2026
Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trialAnthony Stein, Yan Wang, Monzr M Al Malki, et al.
Blood|March 22, 2022
Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICEMatthew G Mei, Hun Ju Lee, Joycelynne M Palmer, et al.
Neuro-Oncology|January 31, 2022
Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastomaChristine E Brown, Analiz Rodriguez, Joycelynne Palmer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 17, 2003
A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcomeH C Fung, A Stein, M l Slovak, et al.
The Lancet. Oncology|December 20, 2014
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyMax S Topp, Nicola Gökbuget, Anthony S Stein, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 4, 2019
Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase MutationsAmandeep Salhotra, Michelle Afkhami, Dongyun Yang, et al.
British Journal of Haematology|December 20, 2016
RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106Robert W Chen, Hongli Li, Steven H Bernstein, et al.
Pageof 106